Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?

Affiliations

Comment

Robert E Pyke. J Sex Med. 2019 Nov.

. 2019 Nov;16(11):1863-1864.

doi: 10.1016/j.jsxm.2019.08.010. Epub 2019 Sep 18.

¹ Pykonsult, LLC, New Fairfield, CT, USA. Electronic address: robertepyke@gmail.com.

No abstract available

Comment in

Response to Letter to the Editor Regarding "Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?".
Althof SE, McMahon CG, Osterloh IH, Muirhead GJ. Althof SE, et al. J Sex Med. 2019 Nov;16(11):1864-1865. doi: 10.1016/j.jsxm.2019.08.023. J Sex Med. 2019. PMID: 31672288 No abstract available.

The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Trial (PEPIX).
McMahon C, Althof S, Rosen R, Giuliano F, Miner M, Osterloh IH, Muirhead GJ, Harty B; PEPIX Multi-Centre Study Group. McMahon C, et al. J Sex Med. 2019 Aug;16(8):1178-1187. doi: 10.1016/j.jsxm.2019.05.016. J Sex Med. 2019. PMID: 31351659 Clinical Trial.
The Oxytocin Antagonist Cligosiban Fails to Prolong Intravaginal Ejaculatory Latency in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Phase IIb trial (PEDRIX).
Althof S, Osterloh IH, Muirhead GJ, George K, Girard N; PEDRIX Multi-Centre Study Group. Althof S, et al. J Sex Med. 2019 Aug;16(8):1188-1198. doi: 10.1016/j.jsxm.2019.05.015. J Sex Med. 2019. PMID: 31351660 Clinical Trial.